Lower Risk of Cardiovascular Death with Tirzepatide in Heart Failure The following is a summary of Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity, published in the November 2024 issue of Endocrinology by Packer et al
It may interact with: Digoxin Fluconazole Indomethacin Lithium It may also interact with certain non-steroidal anti-inflammatory drugs
Most patients notice the first signs of appetite suppression between 37 days after their first injection, though individual timing varies based on genetics, dose, and metabolic factors
There were no statistically significant differences between both groups in terms of other analysed parameters (Table 1)
The major players in the glucagon-like peptide 1 (GLP-1) agonist market are Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer.Inc, Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd, Sun Pharmaceutical Industries Ltd